Etiologics ltd
Related Experiment Video
Updated: Sep 26, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
David A Campbell1, Mary F Fitzgerald
1Etiologics Ltd, Medical Research Council, Harwell, Oxfordshire, OX11 0RD, UK. david.campbell@etiologics.com
Abstract:
Etiologics is an innovative drug discovery company that, unlike most new companies in this sector, has a balanced portfolio of ethylnitrosourea (ENU) technology, animal models of disease, in vitro cell function models, and expertise in drug discovery, which spans the whole drug discovery process. The aim of the company is to identify and develop novel effective therapies for respiratory and metabolic diseases where there is a high unmet medical need. Etiologics also offers partners access to its ENU technology and/or preclinical respiratory models/expertise to enable them to identify/validate new targets and enhance the value of in-house programs.
Related Concept Videos
Encephalitis l: Introduction
Long-term Depression
Calcium Ion Concentration Mechanism
If over time, all...
Long-term Depression
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Chronic Obstructive Pulmonary Disease I: Introduction
Introduction to Language of Pathophysiology l